SEARCH

SEARCH BY CITATION

References

  • 1
    Zaffaroni A. Towards a new concept of precision in drug administration. Pharm J 1970; 205: 400 2.
  • 2
    Zaffaroni A. Alza's approach to controlled medication. Pharm J 1971; 207: 414 5.
  • 3
    Knobil E. The discovery of the hypothalamic gonadotropin-releasing hormone pulse generator and of its physiological significance. Endocrinology 1992; 131: 1005.
  • 4
    Snow J. On Chloroform and Other Anaesthetics: Their Action and Administration. London: John Churchill, 1858.
  • 5
    Perkins L, Peer C, Fleming V. Pumps/Osmotic – ALZET® System. In: MathiowitzE, ed. Encyclopedia of Controlled Drug Delivery, Version 2. New York: John Wiley, 1999: 900 6.
  • 6
    Gusler G & Berner B. Metformin CR™ (Gastric Retentive) tablets: GI transit and pharmacokinetics in healthy volunteers. Conference Abstracts. USA: International Pharmaceutical Federation, 2000: 2 5019.
  • 7
    PROCARDIA-XL (nifedipine). Extended Release Tablets For Oral Use. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 2363 5.
  • 8
    CATAPRES-TTS (clonidine) Transdermal Therapeutic System. Catapres TTS-1, Catapres TTS-2, Catapres TTS-3. Programmed delivery in vivo of 0.1, 0.2, or 0.3 mg per day, for one week. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 795 7.
  • 9
    Wright JC, Stevenson CL, Stewart GL. Pumps/Osmotic – DUROS® Osmotic Implant for Humans. In: MathiowitzE, ed. Encyclopedia of Controlled Drug Delivery, Version 2. New York: John Wiley, 1999: 909 15.
  • 10
    Urquhart J. Can drug delivery systems deliver value in the new pharmaceutical marketplace? Br J Clin Pharmacol 1997; 44: 413 9.
  • 11
    Magruder J. Pumps/Osmotic – VITS Veterinary Implant. In: MathiowitzE, ed. Encyclopedia of Controlled Drug Delivery, Version 2. New York: John Wiley, 1999: 906 9.
  • 12
    Theeuwes F. The elementary osmotic pump. J Pharm Sci 1975; 64: 1987 91.
  • 13
    Theeuwes F, Wong PSL, Yum SI. Drug delivery and therapeutic systems. In: SwarbrickJ, BoylanJC, eds. Encyclopedia of Pharmaceutical Technology, Version 4. New York: Marcel Dekker, 1991: 303 48.
  • 14
    Shaw J & Urquhart J. Programmed, systemic drug delivery by the transdermal route. Trends Pharmacol Sci 1980; 1: 208 11 .
  • 15
    Shaw JE & Urquhart J. Transdermal drug administration – a nuisance becomes an opportunity. BMJ 1981; 283: 875 6.
  • 16
    TRANSDERM SCOP. Scopolamine 1.5 mg Transdermal Therapeutic System Programmed to deliver in-vivo approximately 1.0 mg of scopolamine over 3 days. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 1994 6.
  • 17
    Walt RP, Kalman CJ, Hunt RH, Misiewicz JJ. Effect of transdermally administered hyoscine methobromide on nocturnal acid secretion in patients with duodenal ulcer. BMJ 1982; 284: 1736 8.
  • 18
    Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978; 62: 2011 7.
  • 19
    Fara J & Urquhart J. The value of infusion and injection regimens in assessing efficacy and toxicity of drugs. Trends Pharmacol Sci 1984; 5: 21 5.
  • 20
    Collins JM, Leyland-Jones B, Grieshaber CK. Role of preclinical pharmacology in phase I clinical trials: considerations of schedule-dependence. In: MuggiaFM, ed. Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy. Boston: Martinus-Nijhoff, 1987: 129 40.
  • 21
    http://www.alzet.com[Look for the portion of the bibliography identified as ‘Injection–Infusion Comparisons’.]
  • 22
    Urquhart J, Fara J, Willis K. Rate-controlled delivery systems in drug and hormone research. Ann Rev Pharmacol Toxicol 1984; 24: 199 236.
  • 23
    Nau H, Zierer R, Spielmann H, Neubert D, Gansau C. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 1981; 29: 2803 13.
  • 24
    Nau H & Spielmann H. Embryotoxicity testing of valproic acid. Lancet 1983; 1: 763 4.
  • 25
    Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 26 30.
  • 26
    PROCARDIA nifedipine CAPSULES For Oral Use. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 2361 3.
  • 27
    Duragesic (fentanyl transdermal system). Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 1445 8.
  • 28
    CONCERTA (methylphenidate Hcl) Extended-release Tablets CII. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: (Suppl.) in press.
  • 29
    DEPONIT (nitroglycerine transdermal delivery system). Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000; 2855 6.
  • 30
    NITRO-DUR (nitroglycerin). Transdermal Infusion System. Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 1474 6.
  • 31
    Rhymer AR, Sromovsky JA, Dicenta C, Hart CB. ‘Osmosin’: a multi-centre evaluation of a technological advance in the treatment of osteoarthritis. Curr Med Res Opin 1983; 8(Suppl. 2): 62 71.
  • 32
    Petri H & Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577 81.
  • 33
    Inman B. Comparative study of five NSAIDS. PEM News 1985; 3: 3 13.
  • 34
    Leufkens HG, Urquhart J, Stricker BHC, Bakker A, Petri H. Channeling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Comm Health 1992; 46: 428 32.
  • 35
    Place V, Darley P, Baricevic K, Ramans A, Pruitt B, Guittard G. Human buccal assay for evaluation of the mucosal irritation potential of drugs. Clin Pharmacol Ther 1988; 43: 233 41.
  • 36
    NORPLANT System (levonorgestrel implant). Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co., 2000: 3281 5.
  • 37
    Anonymous. Achievements in Public Health: Family Planning. MMWR , 190099; 48: 1073 80.
  • 38
    Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1993; 68(Suppl. 3): 49 59.
  • 39
    Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49: 321 7.
  • 40
    Kastrissios H & Blaschke TF. Medication compliance as a feature in drug development. Ann Rev Pharmacol Toxicol 1997; 37: 451 75.
  • 41
    Urquhart J. The electronic medication event monitor – lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345 56.
  • 42
    Urquhart J & Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inform J 1988; 22: 363 78.
  • 43
    Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 1993; 54: 242 4.
  • 44
    Gatley MS. To be taken as directed. J R Coll Gen Pract 1968; 16: 39 44.
  • 45
    Anonymous. Helping patients to make the best use of medicines. Drug Therap Bull 1991; 39: 1 2.
  • 46
    Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163 8.
  • 47
    Rudd P, Byyny RL, Zachary V et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 46: 169 76.
  • 48
    Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 453 7.
  • 49
    Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharmacol Ther 2000; 67: 331 4.
  • 50
    NIH Publication 984080. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD. Arch Int Med, 1997; 157: 2413 56.
  • 51
    Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertension 1997; 10: 1097 102.
  • 52
    Mancia G & Grassi G. Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J 1999; 1(Suppl. L): 14 19.
  • 53
    Stephenson J. Noncompliance may cause half of antihypertensive drug ‘failures’. JAMA 1999; 282: 313 4.
  • 54
    Johnson BF & Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Therapeutics 1994; 1: 260 7.
  • 55
    Vaur L, Dutrey-Dupagne C, Boussac J et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995; 26: 127 31.
  • 56
    Leenen FHH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83 8.
  • 57
    Hernandez-Hernandez R, Armas de Hernandez MJ, Armas-Padilla MC, Carvajal AR, Guerrero-Pajuelo J. The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Pressure Monitoring 1996; 1: 1121 6.